BRAF and neoplasm: The study included 3063 patients with a low prevalence of dMMR (5%) and BRAF mutation (8.2%) in the whole studied population, however in patients with dMMR tumours, impaired BRAF was noted more often than in proficient MMR (pMMR) tumours (34.6% vs. 6.8% respectively, p < 0.001).